pentobarbital will reduce the extent or result of cobimetinib by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Prevent coadministration. Powerful or average CYP3A inducers could decrease cobimetinib systemic publicity by >80% and lower its efficacy.benzhydrocodone/acetaminophen and pentobarbital both enhance sedation. Av